|
Activity Number:
|
392
|
|
Type:
|
Invited
|
|
Date/Time:
|
Wednesday, August 1, 2007 : 10:30 AM to 12:20 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #307800 |
|
Title:
|
Applications of RNAi High-Throughput Screening in Drug Discovery
|
|
Author(s):
|
Amy S. Espeseth*+
|
|
Companies:
|
Merck & Co., Inc.
|
|
Address:
|
770 Sumneytown Pike, West Point, PA, 18914,
|
|
Keywords:
|
siRNA ; High Throughput Screening ; cell-based assays
|
|
Abstract:
|
The discovery of RNA interference (RNAi), which allows the targeted degradation of mRNAs using small interfering RNA (siRNA), has revolutionized the identification of drug discovery targets. Following the development of a cell-based assay for human disease, cellular arrays can be treated with siRNA libraries that target thousands of genes. Downregulation of genes associated with the disease state affects the assay output, similar to what would be expected from a small molecule inhibitor. Thus effective siRNAs that are identified in siRNA screens point to potential novel targets for drug discovery programs. Although the number of data points generated by these screens is small compared to a typical small molecule HTS, the number of variables introduced by the use of siRNA typically increases the assay variance, complicating the use of typical QA and hit selection statistical methods.
|
- The address information is for the authors that have a + after their name.
- Authors who are presenting talks have a * after their name.
Back to the full JSM 2007 program |
